NEW YORK, April 22 (Reuters) - Wyeth on Tuesday says it expects to shift marketing away from blockbuster depression drug Effexor this year and instead focus on newer treatment Pristiq, a recently approved derivative of Effexor.
NEW YORK, April 22 (Reuters) - Wyeth on Tuesday says it expects to shift marketing away from blockbuster depression drug Effexor this year and instead focus on newer treatment Pristiq, a recently approved derivative of Effexor.
